Pfizer Leads Rx Rebound At End Of Quarter: Will FDA Appointment Fuel Rally?
Executive Summary
Pfizer's late September rally is an indication that pharmaceutical stocks are living up to their reputation as a secure investment during periods of economic uncertainty.
You may also be interested in...
Lilly Post-Prozac Steps Include Charge Related To Ceclor Manufacturing
Lilly's post-Prozac profit warning includes a charge to eliminate excess manufacturing capacity carried over from the company's last major patent expiration, for the antibiotic Ceclor.
Bristol BuSpar Pediatric Labeling May Delay Second Round Of Generics
The second round of generic approvals for Bristol's anti-anxiety drug BuSpar (buspirone) appears to be held up by Bristol's attempts to enforce exclusivity based on a change in labeling related to pediatric studies.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011